Clinical trials: UC (Urothelial Cancer)
Urothelial Carcinoma
The Cxbladder Monitoring Study
The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated…
- Trial name
- NCT02700659
- Testing
- Cxbladder
- Where
- 11 sites in United States
- Volunteers
- 803 people
- Sponsor
- Pacific Edge Limited
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
This study evaluated the safety and tolerability of epacadostat (INCB024360) administered in combination with atezolizumab (MPDL3280A) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that were…
- Trial name
- NCT02298153
- Testing
- Epacadostat, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
UC (Urothelial Cancer)
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.
- Trial name
- NCT03361865
- Testing
- Pembrolizumab, Epacadostat
- Where
- 143 sites in United States, Australia and 16 more
- Volunteers
- 93 people
- Sponsor
- Incyte Corporation
Urothelial Carcinoma (UC), Peripheral Nerve Disease
Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)
his prospective exploratory study aims to describe the course of peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin in combination with pembrolizumab and…
- Trial name
- ENDEAVOR (NCT07629700)
- Testing
- enfortumab vedotin (EV), PEMBROLIZUMAB (alone or when added to a regimen above), Neuridase
- Volunteers
- 40 people
- Sponsor
- University of Florence
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma (UC)
Korean Prospective Upper Tract Urothelial Carcinoma Cohort
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial…
- Trial name
- NCT07452432
- Testing
- Peripheral blood collection for ctDNA analysis
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation